Skip to Main Content

Author Details

Simeng Suy
MedStar Georgetown University Hospital
1996
106
25
PMIDPaper TitleJournal TitlePublished Year
36826994Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.Acta Oncol2023
37916156Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.Front Oncol2023
38074646Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.Front Oncol2023
37791195Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).Cureus2023
34774650Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.Radiother Oncol2022
35710817Leptin modulated microRNA-628-5p targets Jagged-1 and inhibits prostate cancer hallmarks.Sci Rep2022
35402242Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer.Front Oncol2022
35433457Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer.Front Oncol2022
36620537Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer.Front Oncol2022
35127506Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer.Front Oncol2022
35305936Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.J Sex Med2022
33035622Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.Radiother Oncol2021
33718117Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer.Front Oncol2021
33493615Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.Int J Radiat Oncol Biol Phys2021
33489918Utilization of Iodinated SpaceOAR Vueâ¿¢ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report.Front Oncol2021
33537236Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.Front Oncol2021
33842156Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.Cureus2021
34912703Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.Front Oncol2021
34884984Knockdown of microRNA-214-3p Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Prostate Cancer.Cancers (Basel)2021
34900713Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer.Front Oncol2021
34585025Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.Adv Radiat Oncol2021
34604059Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy.Front Oncol2021
33227392TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation.Int J Biochem Cell Biol2021
32432033Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).Front Oncol2020
32039015Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT).Front Oncol2020
33251131Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer.Front Oncol2020
33425723Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer.Front Oncol2020
32719744Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS â¿¥ 15).Front Oncol2020
32663537Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.Radiother Oncol2020
31009330Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy.OMICS2019
31576546Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients.Adv Exp Med Biol2019
31278310MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells.Sci Rep2019
31276777Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.Int J Radiat Oncol Biol Phys2019
28710895Erectile function after stereotactic body radiotherapy for localized prostate cancer.BJU Int2018
29997466Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer.Curr Urol2018
30254985Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk.Front Oncol2018
29928491TNFAIP8 promotes prostate cancer cell survival by inducing autophagy.Oncotarget2018
29487023Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys2018
28001303Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.Cancer2017
28224113Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.Front Oncol2017
28270015Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.Acta Oncol2017
28343068The role of TRAIL in fatigue induced by repeated stress from radiotherapy.J Psychiatr Res2017
29085804Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer.Front Oncol2017
29052514Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.Radiat Oncol2017
28791252Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?Front Oncol2017
25972264Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.Acta Oncol2016
27663760Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.Int J Radiat Oncol Biol Phys2016
27890426Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.Radiother Oncol2016
27200300Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.Front Oncol2016
27551649The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.Cureus2016
  • 1 - 50 of 106

Recommended Authors

Stephen Greco
Johns Hopkins University School of Medicine
Career Start Year 2012
Number of shared co-authors 26
Ting Martin Ma
University of Washington
Career Start Year 2010
Number of shared co-authors 35
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 14
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 3
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 4
Bradley J Stish
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 29
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 15
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 22
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 3
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 30
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 27
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 16
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 27
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 7
Daniel J Krauss
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 24
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 20
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 6
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 8
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 34
Stanley K Liu
Odette Cancer Centre, University of Toronto
Career Start Year 1995
Number of shared co-authors 4
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 23
Thomas M Pisansky
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 33
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 19
Theodore L DeWeese
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 30
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 11
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 29
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 28
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 12

Collaborators

Sean P Collins
Vanderbilt University School of Medicine
Co-authored papers 97
Anatoly Dritschilo
Co-authored papers 34
Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
Co-authored papers 27
Eric K Oermann
Center for Data Science, New York University
Co-authored papers 15
Constantine A Mantz
University of Chicago
Co-authored papers 8
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 7
Michael L Steinberg
University of California los angeles
Co-authored papers 6
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 6
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 6
Amar U Kishan
University of California los angeles
Co-authored papers 6
Mark K Buyyounouski
Stanford University
Co-authored papers 5
Alan W Katz
University of Rochester
Co-authored papers 5
Hilary P Bagshaw
Stanford University
Co-authored papers 5
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 5
William C Jackson
University of Michigan ann arbor
Co-authored papers 5
Ye Yuan
Southwest Hospital, Army Medical University
Co-authored papers 4
Naomi Y Jiang
University of California los angeles
Co-authored papers 4
Leszek Miszczyk
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 4
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Co-authored papers 4
Bhaskar Kallakury
Georgetown University
Co-authored papers 4
David Shabsovich
university of california los angeles Medical Center
Co-authored papers 3
Rebecca Levin-Epstein
University of California los angeles
Co-authored papers 3
Agnieszka Namys??-Kaletka
Maria Sklodowska-Curie National Research and Institute of Oncology
Co-authored papers 3
Audrey Dang
Tulane University School of Medicine
Co-authored papers 3
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 3
Robert T Dess
University of Michigan ann arbor
Co-authored papers 3
Aleksandra Napieralska
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 3
Shrinivasa K Upadhyaya
University of California davis
Co-authored papers 2
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 2
Jay P Ciezki
Cleveland Clinic
Co-authored papers 2
Release 1.2